Background -Physical activity in daily life and exercise capacity have not been assessed in patients with Crohn's disease to date. Objective -To evaluate the physical activity in daily life, exercise capacity, quality of life, and prevalence of mood disorders in patients with moderate-to-severe Crohn's disease on infliximab-induced remission and the possible associations among variables. Methods -A cross-sectional preliminary study was conducted. Twenty-six patients with Crohn's disease and 20 controls were selected. Participants underwent evaluation of physical activity in daily life (triaxial accelerometer), exercise capacity (shuttle walk test), handgrip strength, quality of life, and presence of mood disorders. Results -The number of steps taken (7446±3081 vs 7898±2487), active time (80.6±42 vs 89.7±24.3min), shuttle walk test distance [665 (405) vs 710 (409) m] and handgrip strength [31 (15) vs 29 (20) kgf did not show any difference between the patients with Crohn's disease and the controls. The time spent lying down [95.8 (68.8) vs 60.9 (74.7) min] was greater and some domains of the quality of life were superior in the patients with Crohn's disease. No correlation was observed between the physical activity in daily life and quality of life or presence of mood disorders in patients with Crohn's disease. Conclusion -Patients with Crohn's disease on infliximab-induced remission, despite to more time spent lying down, they have the same level of physical activity in daily life and exercise capacity min compared with the controls. HEADINGS -Crohn disease. Exercise tolerance. Exercise.
INTRODUCTION
Crohn's disease (CD) is an idiopathic chronic inflammatory disorder of the gastrointestinal tract with a relapsing-remitting course (1) . Although its etiology is not completely known, it is believed that a combination of environmental factors, intestinal microbiota modifications, and dysfunction of the mucosal immune system are involved in its development in genetically susceptible individuals (1) . Over the past 50 years, the incidence of CD and its prevalence rates have been increasing in countries that have adapted a ''westernized'' lifestyle (2, 3) . It is speculated that this phenomenon can be explained, at least in part, by the impact of modifications in dietary habits and sedentary lifestyle on the composition of the gut microbiota (4) .
Physical activity has been associated with the pathogenesis of CD (3) . The benefits of physical activity to patients with CD may be due to modulation of immune function, with suppression of pro-inflammatory factors and an increase of anti-inflammatory mechanisms (5) . These benefits are associated with clinical improvement, as demonstrated by Jones et al., in a prospective study, in which level inflammatory bowel disease (IBD) patients in remission with high exercise levels presented a lower risk of flare up, compared to patients with lower exercise levels (6) . Moreover, regular exercise has other positive impacts such as improvement of nutritional and mood status, improvement of body composition and reduction of bone mineral loss, reduction of fatigue levels, and increase of quality of life (QoL) (7) .
Diarrhea, abdominal pain, anorexia, and weight loss are the main symptoms of CD, and altogether, they result in malnutrition, fatigue, sarcopenia, osteopenia, and osteoporosis (8, 9) , and a higher risk of fractures (10, 11) . The patients with patients encounter difficulties in exercising and frequently present a sedentary lifestyle, which may impair the control of the disease, inducing a vicious cycle (3, 7) .
The use of anti-tumor necrosis factor-alpha (TNF-α) agents, such as infliximab, has markedly changed the treatment of the patients with CD. It has been demonstrated that they not only elicit and maintain remission of the disease, but also reverse some of its deleterious consequences, including muscle wasting and sarcopenia that arise from chronic inflammation (12) . We hypothesized that the patients with CD on infliximab-induced remission have similar levels of exercise capacity and physical activity in daily life as the healthy controls. We conducted this study to assess physical activity in daily life, exercise capacity, QoL and mood disorders in outpatients with infliximab-induced remission of moderate-to-severe CD. We also investigated variables associated with physical activity in daily life.
Measurements and outcomes
After obtaining written informed consent, patients' anthropometric, medical and socio-demographic data were collected. We also obtained disease-associated variables, including duration of disease, location and phenotype of CD according to the Montreal classification, and activity of the disease measured according to the HBI (16) .
Physical activity in daily life
Physical activity in daily life was monitored by a DynaPort activity monitor (McRoberts BV, The Hague, Netherlands), a tri axial accelerometer that measures the time spent in different activities and positions (standing, walking, lying down and sitting), and the number of steps taken. Patients were instructed to place the accelerometer at the waistline and to wear it during the waking periods (12-hour periods) of four consecutive days, including one day of the weekend, except during showers and water activities.
Patients were instructed to maintain normal activity behavior while using the device (17) .
The modified Baecke questionnaire, validated for the Brazilian population, was applied to measure self-reported physical activity. It includes questions about household activities, sports, and leisure time during the last 12 months, as previously described (18) . The sum of the results of the three separated domains yields a final score that classifies the patients into: sedentary (<9); active (9) (10) (11) (12) (13) (14) (15) (16) or athletic (>16).
Exercise capacity
Exercise capacity was evaluated by the shuttle walking test (SWT) (19) . In SWT the patient is instructed to walk up and down a 10 m course separated by cones. An audio sign dictates the speed of which the patient is supposed to walk. Every minute the walking speed increased by a small increment. The test was stopped when the patient was unable to maintain the required speed or showed any symptoms. The total distance indicated the exercise capacity. Vital signs, such as heart rate, blood pressure, and peripheral oxygen saturation were recorded. The modified Borg scale score for evaluation of dyspnea and fatigue was measured before and after SWT (20) .
Peripheral muscle strength
Handgrip strength (HS) is a simple and objective test that evaluates the function of skeletal muscle. HS was performed with a hydraulic dynamometer (SAEHAN, Korea), according to American Society of Hand Therapists recommendations (21) . Three values were obtained with the dominant hand, and the highest value was compared to the normality table based on sex and age (22) .
Quality of life
The QoL was assessed both by the Short Form 36 Healthy Survey (SF-36) and the Inflammatory Bowel Disease Questionnaire (IBDQ), which were previously translated and validated in Brazil (23, 24) . SF-36 is comprised of 36 questions that gather data on: physical health, such as physical functioning, role-physical, bodily pain, and general health; and components related to mental health, specifically, vitality, social functioning, role-emotional and mental health in general. The answers to these questions in each domain are assigned a numerical score, which is coded and classified on a scale from 0 to 100, with 100 being the highest QoL (23) . IBDQ is a specifically designed questionnaire that evaluates the QoLof patients with IBD. It is made up of 32 questions that evaluates different aspects of health quality gathered into four domains: intestinal symptoms, systemic symptoms, social and emotional functions. The score is based on the Likert scale that ranges from 1 to 7, with 1 being the worst state and 7 the best QoL. All the domains are grouped and summed up giving the global score (24) .
Anxiety and depression
Anxiety and depression levels were assessed using the Hospital Anxiety and Depression Scale (HADS), validated for the Brazilian population (25) . It screens for clinically significant anxiety and depressive symptoms in medically ill patients. HADS is composed of 14 items, equally divided into anxiety and depression-related questions. Each item is rated on a 4-point scale, ranging from 0 (no impairment) to 3 (highest impairment). Anxiety and depression scores are considered as the sum of the respective items, ranging from 0 to 21. According to the validated translations of HADS, the cutoff value for depressive or anxiety symptoms is 8.
Statistical analysis
Statistical analysis was performed using SPSS 20.0 (SPSS, Chicago, IL, USA). Initially, normal distribution was validated using a Kolmogorov-Smirnov test. Data were expressed as mean ± standard deviation or median (interquartile range) for symmetrically and asymmetrically distributed data, respectively. Comparisons of frequencies were done by using the χ-squared statistic with Yates' correction. Mean values between two groups were compared using an unpaired Student's t-test or Mann-Whitney U test, for normally and non-normally distributed variables, respectively. Pearson or Spearman correlation coefficients, were used to analyze the relationship between the number of steps/day and other variables of interest. The level of statistical significance was set at P<0.05.
RESULTS
Of the 45 patients screened in the CD group, 26 were included. In the control group, of 40 patients screened, 20 were included (FIGURE 1). Both groups had similar characteristics, except for a lower body mass index in the CD group (TABLE 1) .
The most common location of resection was ileocolic (53.8%) and most patients with CD did not have a history of intestinal resection (73.1%). Perineal disease was observed in only 5 (19%) patients. There were no significant differences between the groups regarding the time spent walking, standing, or sitting. In addition, the number of steps/day values were similar between the groups (CD group vs control group 7446±3081 vs 7898±2487; P=0.63).
The self-reported physical activity was measured by the modified Baecke questionnaire and did not differ between the groups of CD and controls with respect to all domains and the total score [7.24 (4.62) vs 7.13 (4.37), respectively; P=0. 19 ].
There was no difference in the distance walked in the SWT between the groups [median values and quartiles: CD group vs control group 665 (405) vs 710 (409) m; P=0.77]. The HS test results were similar between the groups CD and controls [median values and quartiles: 31 (15) vs 29 (20) kgf; 79.6±17.9 vs 79±24% pred of kgf, respectively; P=0.54 compared to absolute values and P=0.90 to predicted values of normality]. Data are presented in median and on average according to the distribution of the variables. 26 The control patients showed lower SF-36 scores in the pain, vitality, social aspects, and mental health domains compared to the patients with CD (P<0.05). There were no significant differences regarding anxiety and depression scores measured by HADS (TABLE 2) . with CD might be the effects of the anti-TNF-αtherapy on factors of the disease that could impact exercise capacity. High levels of TNF-α have been associated with muscular cell death, sarcopenia, and cachexia in the patients with CD (12) . In contrast, anti-TNF-α therapy with infliximab has been shown to reverse some of these dysfunctions, with improved nutritional status (29) and reversion of inflammatory sarcopenia (2) . In accordance with these studies, our patients, who were in remission, presented normal nutritional status, based on their body mass index; and normal peripheral muscle strength, based on their HF results. Moreover, their exercise capacity was similar to the control group, as observed in SWT; and therefore, was not a limitation to physical activity among the patients with CD in remission.
Anti-TNF-α therapy also can have a positive effect on QoL in patients with CD. It is well known that QoL in patients with IBD, a majority of which have CD, is impaired, but this was not observed in our current study. However, randomized clinical trials have shown that treatment with biological therapy can significantly improve the QoL of patients only after a few months of treatment and lasting for a long period of time (30) (31) (32) (33) (34) . For instance, Feagan et al. (30) . found that baseline scores for a pooled patient population (335 patients) indicated substantial impairment in QoL and after a short period of infliximab therapy, there was significant improvement in IBDQ and SF-36 scores. The authors also showed that scores higher than 170 points in IBDQ corresponded to symptomatic remission of CD. The findings of the current study are in accordance with these findings, since patients with CD showed higher scores in some domains of the SF-36 questionnaire compared to the control group. We hypothesized that the occurrence of lower QoL in the control group could be explained by the visceral hypersensitivity present in functional dyspepsia patients (35) . This control group most likely became more responsive to symptoms than patients with CD that recently to achieved remission.
From a clinical point-of-view, patients with CD should be motivated to increase their level of physical activity in daily life. Even though most patients with CD in this study were classified as somewhat active based on steps/day, 53.8% of these patients did not reach the minimum 7500 steps/day to be characterized as active. It is noteworthy that exercise programs for IBD patients are well tolerated with decreases of disease activity, and functional gains leading to an increased QoL and improved mood (35) . Regular physical activity also improves body composition and decreases fatigue in these patients (35) . Furthermore, several epidemiological studies have linked physical activity during the pre-illness period with reduced risk of IBD onset (36) (37) (38) (39) (40) (41) , and during the illness phase as a possible preventive factor for CD flare ups (36) . It is conceivable that regular moderate aerobic and/or resistance exercises may improve the health status of patients with IBD both by modulating immune function and by improving physical function (35) .
There are a few limitations that should be taken into consideration to adequately qualify our results. Firstly, we did not evaluate the direct effect of infliximab therapy on physical activity in daily life and exercise capacity since a cross-sectional study design was used. Longitudinal studies are required to draw better conclusions on this issue. Secondly, we conducted a single center study with a small sample size, which does not allow for the findings to be generalized for all patients with CD. Thirdly, the selection of patients with functional dyspepsia for the control group could have impacted some points of the analysis since they are not a completely healthy population. No correlation was observed between the level of physical activity and the IBDQ QoL (r=-0.25; P=0. 21) , anxiety scores (r=0.24; P=0.23), or depression scores of the HADS (r=-0.48 P=0.21).
DISCUSSION
This study evaluated the physical activity in daily life, exercise capacity, QoL and mood disorders in patients with CD during infliximab-induced remission compared to control subjects. We found that patients with CD present the same level of physical activity in daily life and exercise capacity when compared to controls, but higher scores in the pain, vitality, social aspects and mental health domains of the SF-36 questionnaire.
An explanation for the same level of physical activity in daily life shown by the patients with CD as the controls is that they were evaluated during the quiescent phase of the disease, in which the symptoms that could lead to a sedentary lifestyle, such as fatigue, muscular and joint pain, and fecal incontinence, are usually absent (26) .
Studies objectively evaluating the level of physical activity in patients with CD are still scarce. Only one of them used an accelerometer in the evaluation of physical activity and showed that patients with CD have sub-optimal physical activity compared to a healthy control group (27) . However, this was a cross-sectional study with a small sample size, with many patients not in clinical or infliximab-induced remission.
A recent article from our group showed muscle functional impairment and poorer quality of life in patients with CD compared to healthy controls (28) . However, the control group consisted of healthy volunteers and the CD group was formed by patients in the active phase of the disease, different from the present study. Another explanation for the physical activity in daily life among the patients
CONCLUSION
Patients with moderate-severe CD on infliximab-induced clinical remission have the same level of physical activity in daily life, and exercise capacity compared to controls subjects, although they spend more time resting. QoL was impaired in domains of pain, vitality, social aspects and mental health in the control patients with functional dyspepsia, probably due to the visceral hypersensitivity of these subjects. However, because asymptomatic patients with quiescent CD have a similar low level of physical activity and more time lying down, it is important for strategies that promote physical activity be a component of regular care for the patients with CD, so that patients may obtain optimal health benefits from exercise. Nonetheless, the real long-term effect of infliximab on physical activity in daily life is not known and further longitudinal studies are needed.
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